GLP-1 receptor agonists are among the most searched medicines in Australia. Here is what a legitimate prescription pathway looks like, what the contraindications are, and how to access them properly.
Start free assessment →This page is for general information purposes only. GLP-1 receptor agonists are prescription-only medicines in Australia requiring assessment by an AHPRA-registered medical practitioner. This page does not constitute medical advice and individual suitability varies.
GLP-1 receptor agonists have become one of the most discussed medical topics in Australia following the surge in awareness of semaglutide and tirzepatide for weight management. Getting a legitimate GLP-1 prescription in Australia requires navigating a healthcare system where these medicines are in high demand and where the distinction between proper medical channels and unregulated access points matters significantly for both safety and legality.
GLP-1 receptor agonists are a class of medicines that work by mimicking or enhancing the action of glucagon-like peptide-1, a naturally occurring hormone involved in glucose regulation, appetite signalling, and gastric emptying. By activating GLP-1 receptors, these medicines reduce appetite, slow gastric emptying, and improve glucose regulation, producing significant reductions in caloric intake and body weight over sustained use.
Semaglutide and tirzepatide are the two most studied compounds in this class for weight management, with large-scale clinical trials demonstrating substantial average weight loss outcomes that have placed them among the most significant pharmacological developments in metabolic medicine in recent decades.
GLP-1 receptor agonists are Schedule 4 prescription-only medicines in Australia. A legitimate prescription requires assessment by an AHPRA-registered medical practitioner who reviews your health history, current medications, weight and metabolic markers, and any contraindications before prescribing. There are specific contraindications for GLP-1 receptor agonists, including personal or family history of certain thyroid conditions and pancreatitis history, that a proper medical assessment identifies.
At UHD BioHealth, GLP-1 receptor agonists are available through our standard assessment pathway where clinically appropriate. The assessment is free, the prescribing doctor reviews your full health picture, and compounds are dispensed through our licensed Australian compounding pharmacy.
GLP-1 and weight regain: Research consistently shows that weight regain occurs after stopping GLP-1 receptor agonist treatment. These medicines appear to work while being taken, with weight returning when treatment stops. This is an important aspect of the evidence to understand before starting, and is one of the reasons why a doctor assessment that takes your long-term health goals and circumstances into account is more useful than simply accessing these medicines independently.
TGA-registered GLP-1 products including Wegovy and Mounjaro are available through Australian pharmacies with a valid prescription. Compounding pharmacy versions of these compounds are also legally accessible through licensed Australian compounding pharmacies against a valid prescription, which can provide an alternative access pathway particularly during periods when registered product supply is constrained.
Both pathways require a valid prescription from an AHPRA-registered doctor. The compounding pathway does not provide a shortcut around the prescription requirement or the need for proper medical assessment.
Complete your health history and goals online. Takes around five minutes and costs nothing.
An AHPRA-registered prescribing doctor reviews your information and prepares a personalised protocol if appropriate.
Once you choose to proceed, your prescription goes to a licensed Australian compounding pharmacy. Cold-chain delivery to your door.
Free assessment, AHPRA-registered prescribing doctor, licensed Australian compounding pharmacy. No cost until you choose to proceed.